N/A
Manufactured by Teva Pharmaceuticals USA, Inc.
22,887 FDA adverse event reports analyzed
Last updated: 2026-04-14
FREMANEZUMAB VFRM is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Teva Pharmaceuticals USA, Inc.. The most commonly reported adverse reactions for FREMANEZUMAB VFRM include ACCIDENTAL EXPOSURE TO PRODUCT, INJECTION SITE PAIN, MIGRAINE, DRUG INEFFECTIVE, HEADACHE. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for FREMANEZUMAB VFRM.
Out of 10,665 classified reports for FREMANEZUMAB VFRM:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 22,887 FDA FAERS reports that mention FREMANEZUMAB VFRM. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include ACCIDENTAL EXPOSURE TO PRODUCT, INJECTION SITE PAIN, MIGRAINE, DRUG INEFFECTIVE, HEADACHE, INJECTION SITE ERYTHEMA. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Teva Pharmaceuticals USA, Inc. in connection with FREMANEZUMAB VFRM. Always verify the specific product and NDC with your pharmacist.